Phio Pharmaceuticals Corp
$ 1.09
2.83%
11 Aug - close price
- Market Cap 12,314,300 USD
- Current Price $ 1.09
- High / Low $ 1.09 / 1.07
- Stock P/E N/A
- Book Value 1.42
- EPS -1.43
- Next Earning Report 2026-08-13
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.47 %
- ROE -0.76 %
- 52 Week High 2.57
- 52 Week Low 0.81
About
Phio Pharmaceuticals Corp. The company is headquartered in Marlborough, Massachusetts.
Analyst Target Price
$14.00
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-07 | 2026-03-05 | 2025-11-13 | 2025-08-14 | 2025-05-15 | 2025-03-31 | 2024-11-14 | 2024-08-14 | 2024-04-01 | 2024-03-20 | 2023-11-09 | 2023-08-10 |
| Reported EPS | -0.34 | -0.15 | -0.44 | -0.45 | -0.41 | -0.85 | -1.54 | -3.62 | -1.53 | -0.85 | -10.26 | -1.4747 |
| Estimated EPS | -0.23 | -0.47 | -0.44 | -0.36 | None | -1.23 | -4.14 | -4.59 | -11.7 | -1.3 | -12.87 | None |
| Surprise | -0.11 | 0.32 | 0 | -0.09 | 0 | 0.38 | 2.6 | 0.97 | 10.17 | 0.45 | 2.61 | 0 |
| Surprise Percentage | -47.8261% | 68.0851% | 0% | -25% | None% | 30.8943% | 62.8019% | 21.1329% | 86.9231% | 34.6154% | 20.2797% | None% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-13 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.36 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: PHIO
2026-08-11 23:46:13
This article provides financial information for Phio Pharmaceuticals Corp. (NASDAQ: PHIO), specifically focusing on its enterprise value to revenue forward. It appears to be a stub or a section of a larger financial data presentation from TradingView, indicating that the value and change details for this metric are available for different periods. The content is primarily a navigation and copyright notice from the financial data provider.
2026-08-11 11:46:13
Phio Pharmaceuticals has received a U.S. Notice of Allowance for a patent covering PH-894, a compound designed to silence BRD4, a gene expression regulator linked to proliferative and infectious diseases. This patent strengthens the company's commitment to advancing PH-894 in the U.S. and seeking international collaborations. The biotechnology firm specializes in immuno-oncology therapeutics using its INTASYL gene-silencing technology, with its lead program, PH-762, targeting the PD-1 gene in skin cancer.
2026-08-11 10:46:13
Phio Pharmaceuticals announced a U.S. Notice of Allowance for a patent covering PH-894, an INTASYL-based compound designed to selectively silence the BRD4 protein, which is linked to proliferative and infectious diseases. This patent strengthens the company's intellectual property portfolio, now comprising 54 issued patents globally for its INTASYL technology. The allowance is crucial for advancing PH-894 in the U.S. and pursuing international collaborations for next-generation cancer therapies.
2026-08-11 10:46:13
Phio Pharmaceuticals has received a U.S. Notice of Allowance for a patent covering PH-894, a compound designed to selectively silence the BRD4 protein, which is linked to proliferative and infectious diseases. This strengthens the company's intellectual property for its INTASYL® gene-silencing technology and supports its strategy to advance PH-894 in the U.S. and seek international collaborations. The patent highlights Phio's commitment to developing novel immuno-oncology therapies and protecting its proprietary innovations.
2026-08-08 13:41:25
Phio Pharmaceuticals Corp (PHIO) has an earnings forecast score of 8.00, placing it 171st out of 387 in the Biotechnology & Medical Research industry. Analysts have set an average price target of $14.00 for PHIO, with a strong buy recommendation based on the rating of one analyst. The company's EPS for the previous quarter was -$0.34, beating the market expectation of -$0.36, and the next quarter's EPS is expected to be -$0.33.
2026-08-07 19:41:06
Phio Pharmaceuticals (NASDAQ: PHIO) reported its second quarter 2026 financial results, highlighting strategic advancements for its lead clinical candidate PH-762. The company made significant progress in its PH-762 development program, including the initiation of commercial-scale API, a long-term non-clinical toxicology study, and the completion of Phase 1b pharmacology. Phio also detailed its financial position, showing cash and cash equivalents of $13.0 million as of June 30, 2026, and an increased net loss due to higher research and development expenses for the PH-762 program.
